🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Thanks to #LesEntreprisescontreleCancerPARISIDF #GEFLUC for their award and financial support to study the mechanisms driving the evolution of IPMN! FHU MOSAIC

Congratulations to Cros Jerome, Rémy Nicolle, Anne Couvelard, Alain Couvineau, Vinciane Rebours, Cecile haumaitre and Lina Aguilera Munoz for winning the Pancreas 2022 call for improving early diagnosis of pancreatic cancer with a focus on preneoplastic lesions #AAPFondationARC

Our CD8 PET study with CD8 imaging before and during immunotherapy in patients with cancer is out “Nat Med”. nature.com/articles/s4159… Thanks to a fantastic team OncoAlert.

Tomorrow : 8:00 AM💡Mosaic' thursdays Pr Cros Jerome & Dr Jules GREGORY will introduce Pancreatic adenocarcinoma: evaluation of the response to radiochemotherapy Moderate by Alain Sauvenet Check out fhu-mosaic.com/les-jeudis-mos… for more information CRI - Centre de Recherche sur l'Inflammation Hôpital Beaujon AP-HP

Great talk Rémy Nicolle ! Lots of hope for improving PDAC TT 💜 #grateful to work with you and Cros Jerome #JFHOD2023

Jeudi #MOSAIC en direct ✌🏻

Jules GREGORY Cros Jerome

Bernoulli_Lab vous présente le projet CLASSTHEP, qui travaille à une classification automatisée des tumeurs intrahépatiques à partir de biopsies de routine, collaboration FHU MOSAIC / équipe OPIS Centre Inria de Saclay CentraleSupélec bernoulli-lab.fr/project/classt…

Le futur de la biopsie 😉🚀🙏FHU MOSAIC Bernoulli_Lab

Today, Nature Communications has published PACpAInt – an innovative #AI model co-developed by Owkin and Assistance Publique – Hôpitaux de Paris (AP-HP), aimed at defining the molecular subtypes of #pancreaticcancer. By utilizing #deeplearning techniques and #digitalpathology, PACpAInt is able to predict pancreatic cancer

From Inserm Rémy Nicolle et al in Nature Communications Pacpaint: a histology-based deep learning model uncovers the extensive intratumor molecular heterogeneity of #PancreaticCancer nature.com/articles/s4146… ~40% of RNA defined “classical” cases harbor “basal-like” component on #AI

Happy to share our work with Owkin on a daring challenge: Can #PDAC epithelial and stromal molecular phenotypes be identified from standard histology slides? Better yet, can this help resolve intra-tumor heterogeneity? a thread 🧵 nature.com/articles/s4146…

But the surprise came from this large number of tumors, about 40% that could we could not simply place at one end of the Basal-like/Classical spectrum This made no sense until we were able to differentiate Hybrid with both phenotypes Intermediary with neither

Still so much to do to understand the origin of such phenotypes and their dynamics Thanks to Owkin for an eye-opening collaboration Flore and Charlie's immense implication Cros Jerome amazing guidance FHU MOSAIC Inserm CRI - Centre de Recherche sur l'Inflammation

Today's Journal of Clinical Oncology article reveals a gemcitabine transcriptomic signature, offering efficacy similar to mFOLFIRINOX but with reduced toxicity. This advance is significant for less fit patients, indicating progress in personalized cancer care. ascopubs.org/doi/10.1200/JC…

Very happy to share our collective work validating the use of predictive RNA based signature to predict gemcitabine sensitivity in a randomised trial. Similar efficacy to FFX in selected patients with much less side effect in the adjuvant setting. ascopubs.org/doi/10.1200/JC…

AI for improving diagnosis of primary liver carcinoma through tumor biopsy 🚀👏 Aurélie Beaufrère FHU MOSAIC 🙏to our collaborators

🚨𝐏𝐚𝐩𝐞𝐫𝐀𝐥𝐞𝐫𝐭🚨FreshOfPress 𝑶𝒖𝒓 #𝑵𝑬𝑻𝑮3𝑵𝑬𝑪 #𝒕𝒖𝒎𝒐𝒓𝒐𝒊𝒅 𝒔𝒄𝒓𝒆𝒆𝒏 npj Journals #LetsTalkAboutNETs #cancer #organoid ex vivo NET Research Foundation Society for Endo 𝐊𝐮𝐝𝐨𝐬 2col Universität Bern Charité - Universitätsmedizin Berlin ngtma @Bernomics Swiss 3R Competence Centre (3RCC) Faculty of Medicine, University of Bern doi.org/10.1038/s41698…

Porte 15

Hot off the press 🔥 Great teamwork pubmed.ncbi.nlm.nih.gov/39612583/ Mural nodules 🧶 and BD IPMN 🍇 MN not always dysplastic (85%) HG dysplasia or 🦀 distant to MN in 45% cases MN not really a good target for local treatment?